Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats
Yan-Qiong Cheng
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Department of Urinary Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China
Yan-Qiong Cheng and Bing-Yi Tan equally contributed to this work.Search for more papers by this authorBing-Yi Tan
Department of Spinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
Yan-Qiong Cheng and Bing-Yi Tan equally contributed to this work.Search for more papers by this authorXu-Hong Yu
Department of Pharmacy, People Liberation Army 305 Hospital, Beijing, China
Search for more papers by this authorWen-Zhe Dong
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Department of Pharmacology, Shanghai Institute of Health Sciences, Shanghai, China
Search for more papers by this authorDing-Feng Su
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Search for more papers by this authorCorresponding Author
De-Qiu Zhu
Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
Correspondence
Ai-Jun Liu, Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China.
Email: [email protected]
and
De-Qiu Zhu, Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Ai-Jun Liu
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Correspondence
Ai-Jun Liu, Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China.
Email: [email protected]
and
De-Qiu Zhu, Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Email: [email protected]
Search for more papers by this authorYan-Qiong Cheng
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Department of Urinary Surgery, Changhai Hospital, Second Military Medical University, Shanghai, China
Yan-Qiong Cheng and Bing-Yi Tan equally contributed to this work.Search for more papers by this authorBing-Yi Tan
Department of Spinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
Yan-Qiong Cheng and Bing-Yi Tan equally contributed to this work.Search for more papers by this authorXu-Hong Yu
Department of Pharmacy, People Liberation Army 305 Hospital, Beijing, China
Search for more papers by this authorWen-Zhe Dong
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Department of Pharmacology, Shanghai Institute of Health Sciences, Shanghai, China
Search for more papers by this authorDing-Feng Su
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Search for more papers by this authorCorresponding Author
De-Qiu Zhu
Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China
Correspondence
Ai-Jun Liu, Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China.
Email: [email protected]
and
De-Qiu Zhu, Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Ai-Jun Liu
Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China
Correspondence
Ai-Jun Liu, Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China.
Email: [email protected]
and
De-Qiu Zhu, Division of Pharmacy, Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Email: [email protected]
Search for more papers by this authorSummary
This study was designed to investigate the possible synergism of amlodipine and candesartan on the reduction of blood pressure (BP) in hypertensive rats. The end organ protection was also observed. In acute experiment, spontaneously hypertensive rats (SHRs) were treated with intragastric administration of amlodipine (0.5, 1, 2, 3 mg/kg), candesartan (1, 2, 3, 4, 6, 8 mg/kg), and 14 different combinations to find the possible ratio of synergistic interaction. In two kidneys, one clip (2K1C) rats, the effects of amlodipine (1 mg/kg), canderastan (2 mg/kg) and their combination on BP reduction were also observed. In chronic study, SHRs were treated with amlodipine (1 mg/kg), candesartan (2 mg/kg), and their combination for 5 months. Organ damage evaluation was performed after BP recording. The probability sum test (q test) was used to evaluate the synergistic action. There is a synergistic interaction between amlodipine and candesartan on BP reduction. The optimal dose ratio is 1:2. The synergistic effect was also confirmed by 2K1C hypertensive rats. In chronic study, this combination (1:2) possessed an obvious synergism on the reduction of BP and BP variability (BPV) and protection on end organs. Multiple regression analysis showed that heart and aortic hypertrophy indexes and glomerular damage parameters were positively related to BP and BPV. In conclusion, combination of amlodipine and candesartan exhibited a potent antihypertensive effect and possessed an obvious synergism on BP reduction and organ protection in hypertension. The optimal proportion was 1:2. BP and BPV reduction may both importantly contribute to end organ protection.
Supporting Information
Filename | Description |
---|---|
cep12901-sup-0001-SupInfo.docWord document, 140.5 KB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957-967.
- 2Yu DD, Pu YH, Pan YS, et al. High blood pressure increases the risk of poor outcome at discharge and 12-month follow-up in patients with symptomatic intracranial large artery stenosis and occlusions: subgroup analysis of the CICAS study. CNS Neurosci Ther. 2015; 21: 530-535.
- 3Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension. 2006; 48: 187-195.
- 4Franco V, Oparil S, Carretero OA. Hypertensive therapy: part II. Circulation. 2004; 109: 3081-3088.
- 5Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. J Hypertens. 2009; 27: 2121-2158.
- 6Wright JT Jr, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA. 2005; 293: 1595-1608.
- 7Gradman AH. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010; 12: 869-878.
- 8Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289: 2560-2572.
- 9Salahuddin A, Mushtaq M, Materson BJ. Combination therapy for hypertension 2013: an update. J Am Soc Hypertens. 2013; 7: 401-407.
- 10Kizilirmak P, Berktas M, Uresin Y, Yildiz OB. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15: 193-200.
- 11Neutel JM, Smith DH. Hypertension management: rationale for triple therapy based on mechanisms of action. Cardiovasc Ther. 2013; 31: 251-258.
- 12Goyal J, Khan ZY, Upadhyaya P, Goyal B, Jain S. Comparative study of high dose mono-therapy of amlodipine or telmisartan, and their low dose combination in mild to moderate hypertension. J Clin Diagn Res 2014; 8: HC08-HC11.
- 13Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906.
- 14Siragy HM. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers. J Hypertens. 2010; 28: 2-8.
- 15Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417-2428.
- 16Shimamoto K, Ando K, Fujita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res. 2014; 37: 253-390.
- 17Kjeldsen SE, Aksnes TA, Ruilope LM. Clinical implications of the 2013 ESH/ESC hypertension guidelines: targets, choice of therapy, and blood pressure monitoring. Drugs R D. 2014; 14: 31-43.
- 18Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2013; 31: 1281-1357.
- 19Yasuno S, Fujimoto A, Nakagawa Y, Kuwahara K, Ueshima K. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther. 2012; 10: 577-583.
- 20Liu W, Wang W, Song SW, et al. Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats. J Cardiovasc Pharmacol. 2011; 57: 308-316.
- 21Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. J Hypertens. 2005; 23: 193-201.
- 22Chandrashekhar Y, Narula J. Death hath a thousand doors to let out life. Circ Res. 2003; 92: 710-714.
- 23Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs candesartan/amlodipine. Hypertens Res. 2007; 30: 831-837.
- 24Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL Jr. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in failure after single therapy (EX-FAST) study. J Clin Hypertens (Greenwich). 2008; 10: 185-194.
- 25Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2007; 25: 1105-1187.
- 26Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009; 32: 3-107.
- 27Su DF, Miao CY. Blood pressure variability and organ damage. Clin Exp Pharmacol Physiol. 2001; 28: 709-715.
- 28Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011; 58: 155-160.
- 29Miao CY, Tao X, Gong K, Zhang SH, Chu ZX, Su DF. Arterial remodeling in chronic sinoaortic-denervated rats. J Cardiovasc Pharmacol. 2001; 37: 6-15.
- 30Koyanagi R, Hagiwara N, Yamaguchi J, et al. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. J Cardiol. 2013; 62: 217-223.
- 31Liu AJ, Zang P, Guo JM, et al. Involvement of acetylcholine-alpha7nAChR in the protective effects of arterial baroreflex against ischemic stroke. CNS Neurosci Ther. 2012; 18: 918-926.
- 32Liu AJ, Guo JM, Liu W, et al. Involvement of arterial baroreflex in the protective effect of dietary restriction against stroke. J Cereb Blood Flow Metab. 2013; 33: 906-913.